Synopsis: Rossari Biotech, a specialty chemicals maker, has reported its highest-ever quarterly revenue of Rs. 697.2 crore for Q1 FY27, up 28 percent year-on-year, though profit growth lagged sharply behind at just 4 percent.
India’s specialty chemicals industry has been navigating a mixed pricing environment, with volume growth staying healthy across personal care, textile and animal health segments even as raw material costs and competitive pricing pressure margins for many mid-sized manufacturers. Rossari’s latest quarter captures both sides of that tension clearly.
Rossari Biotech commands a market capitalisation of Rs. 2,880 crore, with its shares trading at Rs. 520 on 20 July 2026, down 2.15% from the previous close of Rs. 531.45. The stock touched an intraday low of Rs. 514.55 and remains below its 52-week high of Rs. 745.80. It currently trades at a P/E ratio of 19.8x.
What’s the News?
Rossari Biotech announced its financial results for the quarter ended June 30, 2026, reporting consolidated revenue from operations of Rs. 697.2 crore, its highest-ever quarterly figure, up 28 percent from Rs. 543.7 crore in the same quarter last year.
Consolidated EBITDA came in at Rs. 80.6 crore, also a record for the company, up 19 percent from Rs. 67.9 crore a year earlier, though the EBITDA margin slipped to 11.6 percent from 12.5 percent. Consolidated profit after tax grew a comparatively modest 4 percent to Rs. 35.1 crore from Rs. 33.6 crore, with diluted EPS at Rs. 6.3 against Rs. 6.1 previously.
On a standalone basis, the picture looked stronger: revenue rose 32 percent to Rs. 482.3 crore, EBITDA grew 28 percent to Rs. 56.4 crore, and PAT jumped 31 percent to Rs. 34.3 crore from Rs. 26.2 crore, suggesting the gap between consolidated and standalone growth stems largely from performance at the subsidiary level rather than the core Indian business.
Promoters Edward Menezes and Sunil Chari, in a joint statement, attributed the quarter’s revenue growth to healthy momentum in the domestic business and continued expansion overseas, with the company’s three business segments, Home Personal Care and Performance Chemicals, Textile Specialty Chemicals, and Animal Health and Nutrition, each growing between 27 and 28 percent year-on-year.
The company also flagged two other developments for the quarter: the establishment of a greenfield blending facility in Thailand through its subsidiary Unistar Thai, with an installed capacity of 5,000 metric tonnes per annum, and the completion of the sale of its Andheri office, extending a run of non-core asset monetisation that began with the sale of its Kanjurmarg office the previous quarter.
Financial & Business Analysis
The headline numbers for Rossari this quarter cut in two directions. Revenue and EBITDA both hit record highs and grew faster than the specialty chemicals sector typically manages, which speaks well of the company’s ability to win volume across its three segments and its expanding international footprint out of the new Thailand facility.
The concerning part is margin compression: consolidated EBITDA margin fell a full percentage point to 11.6 percent, and PAT growth of just 4 percent lagged far behind the 28 percent revenue growth, meaning a meaningful chunk of the additional business this quarter came in at lower profitability than the company’s existing book.
That gap between consolidated and standalone growth also deserves scrutiny. If the parent company’s own numbers grew 31% percent while the consolidated figure grew only 4 percent, one or more subsidiaries likely dragged down group profitability, and investors would benefit from Rossari clarifying which entities are behind that divergence in its investor call.
Zooming out to the full year, Rossari closed FY26 with revenue of Rs. 2,396.4 crore, up 15 percent, and EBITDA of Rs. 286 crore, up 8 percent, so this quarter’s 28 percent revenue growth marks a clear acceleration versus the company’s own recent trend, even if profitability has not kept pace with that faster topline.
Industry & Strategic Analysis
Rossari’s new 5,000 MTPA blending facility in Thailand strengthens its presence in Southeast Asia by enabling faster deliveries, customised formulations, and improved supply-chain efficiency. The move supports the company’s broader strategy of expanding its international footprint and increasing export contributions across high-growth specialty chemical markets.
The company’s diversified portfolio across HPPC, textile chemicals, and animal health continues to provide balanced growth. Demand remains healthy across multiple end-user industries, while deeper customer engagement, new applications, and increasing acceptance of differentiated specialty products are supporting market share gains.
Rossari is also benefiting from its past investments in manufacturing capacity, R&D, and strategic acquisitions. Improving utilisation levels at newly added facilities and synergies from businesses such as Unitop and Tristar are expected to enhance operating efficiencies and support future profitability.
The ongoing monetisation of non-core assets and a relatively healthy balance sheet provide additional financial flexibility. With net debt-to-equity standing at just 0.21x in FY26, Rossari remains well positioned to fund future expansion initiatives while maintaining a disciplined capital allocation approach.
Company Overview
Rossari Biotech is a Mumbai-headquartered specialty chemicals manufacturer with facilities at Silvassa and Dahej, serving the Home, Personal Care and Performance Chemicals, Textile Specialty Chemicals, and Animal Health and Nutrition segments. Listed on the BSE (543213) and NSE (ROSSARI), the company caters to FMCG, industrial cleaning, personal care and pet care industries through an extensive distributor network across India.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
